Elevated Serum Pentosidine and Decreased Serum IGF-I Levels are Associated with Loss of Muscle Mass in Postmenopausal Women with Type 2 Diabetes Mellitus

Abstract

Advanced glycation end-products (AGEs) play important roles in the progression of diabetic complications. Although sarcopenia is recently recognized as another complication associated with diabetes mellitus, its mechanism still remains unclear. In this study, we investigated the relationship between serum levels of pentosidine, which is one of AGEs, and insulin-like growth factor-I (IGF-I) vs. skeletal muscle mass by whole body dual-energy x-ray absorptiometry in 133 postmenopausal women with type 2 diabetes. Relative skeletal muscle mass index (RSMI) was calculated by following formula; appendicular skeletal muscle mass divided by height in meters squared. Simple correlation analyses showed that serum pentosidine levels were significantly and negatively correlated with muscle mass of legs (r=−0.21, p=0.017) and RSMI (r=−0.18, p=0.022), and that IGF-I was significantly and positively correlated with muscle mass of arms and legs (r=0.23, p=0.008 and r=0.30, p=0.001, respectively) as well as RSMI (r=0.20, p=0.022). Moreover, after adjusting for age, duration of diabetes, serum creatinine, HbA1c, and IGF-I, pentosidine was significantly and negatively associated with RSMI (β=−0.27, p=0.018) and marginally with muscle mass of legs (β=−0.18, p=0.071). The associations between IGF-I and indices of muscle mass such as arms, legs and RSMI were still significant after additional adjustment for pentosidine (p=0.016, 0.019 and 0.021, respectively). These findings indicate that increased serum pentosidine and decreased IGF-I are independent risk factors for loss of muscle mass in postmenopausal women with type 2 diabetes.

Key words

pentosidine - skeletal muscle mass - sarcopenia - diabetes mellitus - IGF-I

• References

• 1 Park SW, Goodpaster BH, Strotmeyer ES et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care 2007; 30: 1507-1512
• 2 Tajiri Y, Kato T, Nakayama H et al. Reduction of skeletal muscle, especially in lower limbs, in Japanese type 2 diabetic patients with insulin resistance and cardiovascular risk factors. Metab Syndr Relat Disord 2010; 8: 137-142
• 3 Andersen H, Nielsen S, Mogensen CE et al. Muscle strength in type 2 diabetes. Diabetes 2004; 53: 1543-1548
• 4 Park SW, Goodpaster BH, Lee JS et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 2009; 32: 1993-1997
• 5 Singh R, Barden A, Mori T et al. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146
• 6 Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101
• 7 Lukic IK, Humpert PM, Nawroth PP et al. The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy. Ann N Y Acad Sci 2008; 1126: 76-80
• 8 Yu Y, Thorpe SR, Jenkins AJ et al. Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes. Diabetologia 2006; 49: 2488-2498
• 9 Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci 2010; 51: 4867-4874
• 10 Stitt AW, Bhaduri T, McMullen CB et al. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell Biol Res Commun 2000; 3: 380-388
• 11 Yamagishi S, Inagaki Y, Okamoto T et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002; 277: 20309-20315
• 12 Ogawa N, Yamaguchi T, Yano S et al. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 2007; 39: 871-875
• 13 Okazaki K, Yamaguchi T, Tanaka K et al. Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis. Calcif Tissue Int 2012; 91: 286-296
• 14 Tanaka K, Yamaguchi T, Kaji H et al. Advanced glycation end products suppress osteoblastic differentiation of stromal cells by activating endoplasmic reticulum stress. Biochem Biophys Res Commun 2013; 438: 463-467
• 15 Yamamoto M, Yamaguchi T, Yamauchi M et al. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 1013-1019
• 16 de la Maza MP, Uribarri J, Olivares D et al. Weight increase is associated with skeletal muscle immunostaining for advanced glycation end products, receptor for advanced glycation end products, and oxidation injury. Rejuvenation Res 2008; 11: 1041-1048
• 17 Haus JM, Carrithers JA, Trappe SW et al. Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle. J Appl Physiol 2007; 103: 2068-2076
• 18 Sun K, Semba RD, Fried LP et al. Elevated Serum Carboxymethyl-Lysine, an Advanced Glycation End Product, Predicts Severe Walking Disability in Older Women: The Women’s Health and Aging Study I. J Aging Res 2012; 2012: 586385
• 19 Tanaka K, Kanazawa I, Yamaguchi T et al. Active vitamin D possesses beneficial effects on the interaction between muscle and bone. Biochem Biophys Res Commun 2014; 450: 482-487
• 20 Kostka T, Arsac LM, Patricot MC et al. Leg extensor power and dehydroepiandrosterone sulfate, insulin-like growth factor-I and testosterone in healthy active elderly people. Eur J Appl Physiol 2000; 82: 83-90
• 21 Adams GR, McCue SA. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol 1998; 84: 1716-1722
• 22 Schiaffino S, Dyar KA, Ciciliot S et al. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J 2013; 280: 4294-4314
• 23 Cappola AR, Bandeen-Roche K, Wand GS et al. Association of IGF-I levels with muscle strength and mobility in older women. J Clin Endocrinol Metab 2001; 86: 4139-4146
• 24 Rosato MT, Schneider SH, Shapses SA. Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calfic Tissue Int 1998; 63: 107-111
• 25 Kanazawa I, Yamaguchi T, Sugimoto T. Effects of intensive glycemic control on serum levels of insulin-like growth factor-I and dehydroepiandrosterone sulfate in type 2 diabetes mellitus. J Endocrinol Invest 2012; 35: 469-472
• 26 Kanazawa I, Yamaguchi T, Sugimoto T. Serum insulin-like growth factor-I is amarker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2011; 22: 1191-1198
• 27 Kanazawa I, Yamamoto M, Yamaguchi T et al. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 362-365
• 28 King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431
• 29 Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-423
• 30 Sanada K, Miyachi M, Tanimoto M et al. A cross-sectional study of sarcopenia in Japanese men and women: reference values and association with cardiovascular risk factors. Eur J Appl Physiol 2010; 110: 57-65
• 31 Kanazawa I, Yamamoto M, Yamaguchi T et al. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 362-365
• 32 Tam HL, Shiu SW, Wong Y et al. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010; 209: 173-177
• 33 Bonfante L, Virga G, Lapolla A et al. Suspension of ACE-I and ARB treatment is associated with acute increase in serum AGE levels in patients on peritoneal dialysis. Perit Dial Int 2011; 31: 94-97
• 34 Matsui T, Yamagishi S, Takeuchi M et al. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res 2010; 61: 34-39
• 35 Yoshida N, Okumura K, Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 2005; 54: 345-365
• 36 Jack M, Wright D. Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. Transl Res 2012; 159: 355-365
• 37 Thraikill KM. Insulin-like growth factor-I in dibetes mellitus: its physiology, metabolic effects, and potential clinical utility. Diab Technol Ther 2000; 2: 69-80
• 38 Whiting DR, Guariguata L, Weil C et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321